CPA
KYTX icon

Capital Performance Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Capital Performance Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$39 – 2783
2024
Q3 		$39 Buy
+8
New +$62 ﹤0.01% 2815

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Performance Advisors's KYTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 8 shares — an estimated $39 sold.

Capital Performance Advisors first reported a position in KYTX in Q3 2024 and held it in 1 quarter. The position peaked at $39 in Q3 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 8 Kyverna Therapeutics shares in Q4 2024, an estimated $39.
  • Capital Performance Advisors first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Kyverna Therapeutics position peaked at $39 in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.